Hims & Hers has seen a significant rise in its stock price, driven by optimistic movements from the FDA regarding peptide regulations. With the FDA planning to review the restrictions on certain unapproved peptides, analysts believe this could represent a substantial opportunity for the company. The advisory committee is set to discuss broader access to these peptides, which have gained popularity amid a wellness trend. Notably, figures like RFK Jr. are influencing these regulatory considerations, causing the market to react positively. Hims & Hers stocks rose as much as 14%, and analysts have raised their price targets, suggesting a potential revenue boom in the near future as the landscape for peptide therapies appears to evolve.